Tau Protein as a New Regulator of Cellular Prion Protein Transcription.


Journal

Molecular neurobiology
ISSN: 1559-1182
Titre abrégé: Mol Neurobiol
Pays: United States
ID NLM: 8900963

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 19 03 2020
accepted: 14 07 2020
pubmed: 20 7 2020
medline: 10 6 2021
entrez: 20 7 2020
Statut: ppublish

Résumé

Cellular prion protein (PrP

Identifiants

pubmed: 32683652
doi: 10.1007/s12035-020-02025-x
pii: 10.1007/s12035-020-02025-x
doi:

Substances chimiques

Amyloid beta-Peptides 0
Ligands 0
Prion Proteins 0
Protein Kinase Inhibitors 0
Reactive Oxygen Species 0
tau Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4170-4186

Subventions

Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : RTI2018-099773-B-I00
Organisme : Generalitat de Catalunya
ID : SGR2017-648
Organisme : ciberned
ID : PRY-2018-2
Organisme : "la Caixa" Foundation
ID : LCF/PR/HR19/52160007
Organisme : Spanish prion network
ID : AGL2017-90665-REDT

Auteurs

Laia Lidón (L)

Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Scientific Park of Barcelona, The Barcelona Institute for Science and Technology (BIST), Baldiri and Reixac 15-21, 08028, Barcelona, Spain.
Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Av. Diagonal 643, 08028, Barcelona, Spain.
Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.
Institute of Neuroscience, University of Barcelona, Barcelona, Spain.

Cristina Vergara (C)

Laboratory of Histology, Neuroanatomy and Neuropathology, UNI (ULB Neuroscience Institute), Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium.

Isidro Ferrer (I)

Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.
Institute of Neuroscience, University of Barcelona, Barcelona, Spain.
Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain.
Bellvitge University Hospital, IDIBELL (Bellvitge Biomedical Research Centre), Barcelona, Spain.

Félix Hernández (F)

Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.
Center of Molecular Biology "Severo Ochoa" (CSIC-UAM), Madrid, Spain.

Jesús Ávila (J)

Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain.
Center of Molecular Biology "Severo Ochoa" (CSIC-UAM), Madrid, Spain.

Jose A Del Rio (JA)

Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Scientific Park of Barcelona, The Barcelona Institute for Science and Technology (BIST), Baldiri and Reixac 15-21, 08028, Barcelona, Spain. jadelrio@ibecbarcelona.eu.
Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Av. Diagonal 643, 08028, Barcelona, Spain. jadelrio@ibecbarcelona.eu.
Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain. jadelrio@ibecbarcelona.eu.
Institute of Neuroscience, University of Barcelona, Barcelona, Spain. jadelrio@ibecbarcelona.eu.

Rosalina Gavín (R)

Molecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia (IBEC), Scientific Park of Barcelona, The Barcelona Institute for Science and Technology (BIST), Baldiri and Reixac 15-21, 08028, Barcelona, Spain. rgavin@ub.edu.
Department of Cell Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Av. Diagonal 643, 08028, Barcelona, Spain. rgavin@ub.edu.
Network Centre of Biomedical Research of Neurodegenerative Diseases (CIBERNED), Institute of Health Carlos III, Ministry of Economy and Competitiveness, Madrid, Spain. rgavin@ub.edu.
Institute of Neuroscience, University of Barcelona, Barcelona, Spain. rgavin@ub.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH